To the Editor: In a recent issue of BLOOD, Yin et al[1][1]reported the production of AC133, a monoclonal antibody (MoAb) that binds to a novel cell surface antigen present on a CD34(bright) subset of human hematopoietic stem cells (HSCs). In the same issue, Miraglia et al[2][2] described that the
No takes yet. Share an insight, caveat, or question.
Horn et al. (1999) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: